NASDAQ:LVTX

Lava Therapeutics B.V. Competitors

$11.03
-0.10 (-0.90 %)
(As of 06/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.00
$11.13
50-Day Range
$10.80
$15.62
52-Week Range
$9.76
$17.20
Volume6,109 shs
Average Volume63,592 shs
Market Capitalization$279.63 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Lava Therapeutics B.V. (NASDAQ:LVTX) Vs. JYNT, CHRS, ATRI, NXGN, CGEM, and PCVX

Should you be buying LVTX stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Lava Therapeutics B.V., including The Joint (JYNT), Coherus BioSciences (CHRS), Atrion (ATRI), NextGen Healthcare (NXGN), Cullinan Oncology (CGEM), and Vaxcyte (PCVX).

The Joint (NASDAQ:JYNT) and Lava Therapeutics B.V. (NASDAQ:LVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

82.1% of The Joint shares are held by institutional investors. Comparatively, 36.3% of Lava Therapeutics B.V. shares are held by institutional investors. 4.6% of The Joint shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares The Joint and Lava Therapeutics B.V.'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Joint$58.68 million18.92$13.17 million$0.30260.10
Lava Therapeutics B.V.N/AN/AN/AN/AN/A

The Joint has higher revenue and earnings than Lava Therapeutics B.V..

Analyst Recommendations

This is a breakdown of recent ratings for The Joint and Lava Therapeutics B.V., as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Joint01402.80
Lava Therapeutics B.V.00303.00

The Joint presently has a consensus target price of $55.40, indicating a potential downside of 29.00%. Lava Therapeutics B.V. has a consensus target price of $23.6667, indicating a potential upside of 114.57%. Given Lava Therapeutics B.V.'s stronger consensus rating and higher possible upside, analysts plainly believe Lava Therapeutics B.V. is more favorable than The Joint.

Profitability

This table compares The Joint and Lava Therapeutics B.V.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Joint23.43%37.82%9.85%
Lava Therapeutics B.V.N/AN/AN/A

Summary

The Joint beats Lava Therapeutics B.V. on 7 of the 9 factors compared between the two stocks.

Coherus BioSciences (NASDAQ:CHRS) and Lava Therapeutics B.V. (NASDAQ:LVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

36.3% of Lava Therapeutics B.V. shares are held by institutional investors. 13.0% of Coherus BioSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Coherus BioSciences and Lava Therapeutics B.V.'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coherus BioSciences$475.82 million2.33$132.24 million$1.629.04
Lava Therapeutics B.V.N/AN/AN/AN/AN/A

Coherus BioSciences has higher revenue and earnings than Lava Therapeutics B.V..

Analyst Recommendations

This is a breakdown of recent ratings for Coherus BioSciences and Lava Therapeutics B.V., as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Coherus BioSciences01402.80
Lava Therapeutics B.V.00303.00

Coherus BioSciences presently has a consensus target price of $24.8333, indicating a potential upside of 69.63%. Lava Therapeutics B.V. has a consensus target price of $23.6667, indicating a potential upside of 114.57%. Given Lava Therapeutics B.V.'s stronger consensus rating and higher possible upside, analysts plainly believe Lava Therapeutics B.V. is more favorable than Coherus BioSciences.

Profitability

This table compares Coherus BioSciences and Lava Therapeutics B.V.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Coherus BioSciences-17.23%-34.76%-9.86%
Lava Therapeutics B.V.N/AN/AN/A

Summary

Lava Therapeutics B.V. beats Coherus BioSciences on 6 of the 9 factors compared between the two stocks.

Atrion (NASDAQ:ATRI) and Lava Therapeutics B.V. (NASDAQ:LVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Valuation and Earnings

This table compares Atrion and Lava Therapeutics B.V.'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atrion$147.59 million7.50$32.12 millionN/AN/A
Lava Therapeutics B.V.N/AN/AN/AN/AN/A

Atrion has higher revenue and earnings than Lava Therapeutics B.V..

Insider and Institutional Ownership

65.6% of Atrion shares are held by institutional investors. Comparatively, 36.3% of Lava Therapeutics B.V. shares are held by institutional investors. 22.0% of Atrion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Atrion and Lava Therapeutics B.V., as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atrion0000N/A
Lava Therapeutics B.V.00303.00

Lava Therapeutics B.V. has a consensus target price of $23.6667, indicating a potential upside of 114.57%. Given Lava Therapeutics B.V.'s higher possible upside, analysts plainly believe Lava Therapeutics B.V. is more favorable than Atrion.

Profitability

This table compares Atrion and Lava Therapeutics B.V.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atrion21.61%12.94%11.69%
Lava Therapeutics B.V.N/AN/AN/A

Summary

Atrion beats Lava Therapeutics B.V. on 6 of the 8 factors compared between the two stocks.

NextGen Healthcare (NASDAQ:NXGN) and Lava Therapeutics B.V. (NASDAQ:LVTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Valuation & Earnings

This table compares NextGen Healthcare and Lava Therapeutics B.V.'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NextGen Healthcare$556.82 million1.99$9.52 million$0.7222.93
Lava Therapeutics B.V.N/AN/AN/AN/AN/A

NextGen Healthcare has higher revenue and earnings than Lava Therapeutics B.V..

Insider & Institutional Ownership

74.1% of NextGen Healthcare shares are owned by institutional investors. Comparatively, 36.3% of Lava Therapeutics B.V. shares are owned by institutional investors. 18.7% of NextGen Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for NextGen Healthcare and Lava Therapeutics B.V., as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NextGen Healthcare23402.22
Lava Therapeutics B.V.00303.00

NextGen Healthcare currently has a consensus price target of $21.00, indicating a potential upside of 27.20%. Lava Therapeutics B.V. has a consensus price target of $23.6667, indicating a potential upside of 114.57%. Given Lava Therapeutics B.V.'s stronger consensus rating and higher possible upside, analysts plainly believe Lava Therapeutics B.V. is more favorable than NextGen Healthcare.

Profitability

This table compares NextGen Healthcare and Lava Therapeutics B.V.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NextGen Healthcare1.71%12.44%7.63%
Lava Therapeutics B.V.N/AN/AN/A

Summary

NextGen Healthcare beats Lava Therapeutics B.V. on 7 of the 9 factors compared between the two stocks.

Cullinan Oncology (NASDAQ:CGEM) and Lava Therapeutics B.V. (NASDAQ:LVTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Valuation & Earnings

This table compares Cullinan Oncology and Lava Therapeutics B.V.'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan OncologyN/AN/A$-51,800,000.00($5.48)-4.63
Lava Therapeutics B.V.N/AN/AN/AN/AN/A

Insider & Institutional Ownership

72.0% of Cullinan Oncology shares are owned by institutional investors. Comparatively, 36.3% of Lava Therapeutics B.V. shares are owned by institutional investors. 21.8% of Cullinan Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Cullinan Oncology and Lava Therapeutics B.V., as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cullinan Oncology00403.00
Lava Therapeutics B.V.00303.00

Cullinan Oncology currently has a consensus price target of $51.75, indicating a potential upside of 103.90%. Lava Therapeutics B.V. has a consensus price target of $23.6667, indicating a potential upside of 114.57%. Given Lava Therapeutics B.V.'s higher possible upside, analysts plainly believe Lava Therapeutics B.V. is more favorable than Cullinan Oncology.

Profitability

This table compares Cullinan Oncology and Lava Therapeutics B.V.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cullinan OncologyN/AN/AN/A
Lava Therapeutics B.V.N/AN/AN/A

Summary

Cullinan Oncology beats Lava Therapeutics B.V. on 3 of the 4 factors compared between the two stocks.

Vaxcyte (NASDAQ:PCVX) and Lava Therapeutics B.V. (NASDAQ:LVTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Valuation & Earnings

This table compares Vaxcyte and Lava Therapeutics B.V.'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A$-89,220,000.00($3.02)-7.11
Lava Therapeutics B.V.N/AN/AN/AN/AN/A

Insider & Institutional Ownership

85.7% of Vaxcyte shares are owned by institutional investors. Comparatively, 36.3% of Lava Therapeutics B.V. shares are owned by institutional investors. 21.7% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Vaxcyte and Lava Therapeutics B.V., as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaxcyte00403.00
Lava Therapeutics B.V.00303.00

Vaxcyte currently has a consensus price target of $48.00, indicating a potential upside of 123.46%. Lava Therapeutics B.V. has a consensus price target of $23.6667, indicating a potential upside of 114.57%. Given Vaxcyte's higher possible upside, equities research analysts plainly believe Vaxcyte is more favorable than Lava Therapeutics B.V..

Profitability

This table compares Vaxcyte and Lava Therapeutics B.V.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VaxcyteN/A-23.46%-20.89%
Lava Therapeutics B.V.N/AN/AN/A

Summary

Vaxcyte beats Lava Therapeutics B.V. on 4 of the 6 factors compared between the two stocks.


Lava Therapeutics B.V. Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
The Joint logo
JYNT
The Joint
1.5$78.03-0.3%$1.11 billion$58.68 million78.03
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.3$14.64-2.9%$1.11 billion$475.82 million-12.00
Atrion logo
ATRI
Atrion
1.2$605.90-3.8%$1.11 billion$147.59 million35.92High Trading Volume
News Coverage
NextGen Healthcare logo
NXGN
NextGen Healthcare
1.6$16.51-0.8%$1.11 billion$556.82 million110.07News Coverage
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.8$25.38-1.7%$1.10 billionN/A-4.63
Vaxcyte logo
PCVX
Vaxcyte
1.6$21.48-0.7%$1.10 billionN/A-7.28
Endo International logo
ENDP
Endo International
1.7$4.73-0.8%$1.10 billion$2.90 billion11.83News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$14.41-4.3%$1.10 billion$17.40 million-6.27
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.8$21.36-2.3%$1.09 billionN/A-5.17
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$34.78-2.2%$1.09 billionN/A-8.28Insider Selling
News Coverage
Mesoblast logo
MESO
Mesoblast
1.4$8.39-2.4%$1.09 billion$32.16 million-8.83
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$16.65-4.8%$1.09 billion$71.86 million-3.85Analyst Report
News Coverage
908 Devices logo
MASS
908 Devices
1.9$39.74-0.2%$1.08 billion$26.89 million-32.05Insider Selling
News Coverage
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.8$31.01-4.5%$1.08 billionN/A-2.74
Immunovant logo
IMVT
Immunovant
1.8$11.00-0.8%$1.08 billionN/A-8.87
Humanigen logo
HGEN
Humanigen
2.0$18.15-1.7%$1.07 billion$310,000.00-5.35Insider Selling
OLMA
Olema Pharmaceuticals
1.9$26.64-1.9%$1.07 billionN/A-7.79Insider Selling
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.5$54.37-1.4%$1.07 billion$187.13 million-494.23
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
2.0$29.74-4.4%$1.07 billion$41.82 million-9.78Insider Selling
MNMD
Mind Medicine (MindMed)
1.0$3.47-3.5%$1.06 billionN/A0.00
CNTB
Connect Biopharma
1.7$18.48-3.9%$1.06 billionN/A0.00
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.6$10.28-3.4%$1.06 billion$150,000.0060.47
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.5$9.25-3.2%$1.06 billion$46.55 million-11.42
Varex Imaging logo
VREX
Varex Imaging
1.1$26.92-0.9%$1.06 billion$738.30 million-18.31News Coverage
KNTE
Kinnate Biopharma
2.0$24.16-4.3%$1.05 billionN/A-4.58
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.6$18.90-0.6%$1.05 billion$248.17 million33.16News Coverage
AngioDynamics logo
ANGO
AngioDynamics
1.4$27.48-2.5%$1.05 billion$264.16 million-6.23
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.7$20.82-1.2%$1.05 billionN/A-15.20
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$44.57-18.0%$1.04 billion$10 million-18.65Analyst Report
News Coverage
Gap Down
SI-BONE logo
SIBN
SI-BONE
1.9$31.43-0.1%$1.03 billion$73.39 million-22.13
Bioventus logo
BVS
Bioventus
1.5$17.94-1.3%$1.02 billion$321.16 million2.37Analyst Downgrade
SKIN
The Beauty Health
1.5$17.60-1.3%$1.01 billionN/A0.00
Inhibrx logo
INBX
Inhibrx
1.6$26.75-6.3%$1.01 billion$12.89 million-8.89
So-Young International logo
SY
So-Young International
1.1$9.22-2.7%$1.00 billion$198.47 million-922.00
VBI Vaccines logo
VBIV
VBI Vaccines
1.6$3.90-0.3%$991.36 million$1.06 million-16.96News Coverage
Scholar Rock logo
SRRK
Scholar Rock
1.5$28.76-4.2%$989.78 million$15.40 million-9.62
NTUS
Natus Medical
1.1$29.04-0.3%$989.63 million$415.68 million-90.75
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.6$14.32-0.2%$977.08 millionN/A-5.08
Cerus logo
CERS
Cerus
1.0$5.70-1.6%$975.68 million$91.92 million-15.83
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.5$27.95-1.3%$973.39 millionN/A-11.22Analyst Upgrade
News Coverage
Apria logo
APR
Apria
2.1$27.57-1.4%$971.93 million$1.11 billion0.59
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$13.94-1.1%$969.69 million$830,000.00-8.82
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.3$20.31-0.5%$967.47 million$349.85 million406.20
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$47.82-3.0%$965.73 million$122.47 million-13.03News Coverage
Omeros logo
OMER
Omeros
1.6$15.45-0.1%$962.97 million$73.81 million-6.33
Vaxart logo
VXRT
Vaxart
1.3$7.85-0.5%$959.80 million$4.05 million-16.70
ViewRay logo
VRAY
ViewRay
1.3$5.92-1.5%$957.50 million$57.02 million-8.22
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.7$25.07-0.8%$956.52 millionN/A-2.31News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$17.13-3.0%$956.08 million$13.64 million-3.98High Trading Volume
News Coverage
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
2.2$25.14-0.8%$953.23 millionN/A-7.39
This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.